|Awarded On||February 16, 2022|
|Title||Targeting SMARCA4 Mutations in Pediatric Burkitt Lymphoma|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Michael Green|
Pediatric Burkitt lymphoma (pBL) is the most frequent pediatric lymphoma and has a median onset of 10 years old. Although a large fraction of patients can be cured with high-dose combination chemotherapy, long-term survivors often suffer from treatment-associated morbidity and those that relapse have dismal outcomes.
This highlights a need for better understanding of disease mechanisms so that we can design more effective and less toxic therapies. The cell of origin for pBL arises from B-cells that are undergoing a natural process of proliferation and mutation in response to an antigen, within a microphysiological structure called the germinal center (GC). Under normal circumstances, develo...